Leadership


  • Headshot of Gemma.
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip
    Sponsored by AstraZeneca

    Transforming blood cancer care to make a difference for patients

    AstraZeneca’s Gemma Satterthwaite talks to the company’s ambition to transform the entire care experience for patients with blood cancers.

    Dec. 4, 2023
  • Portrait of John Mulligan, chief executive officer of Bonum.
    Image attribution tooltip
    Permission granted by Bonum Therapeutics
    Image attribution tooltip

    How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

    John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

    By Nov. 30, 2023
  • clinical trial diversity Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • A printed copy of the 2017 Tax Cut and Jobs Act is seen lying on a desk with other papers.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip
    Deep Dive

    Pharma benefited from basing business overseas. An international tax effort could spur a rethink.

    U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.

    By Jonathan Gardner • Nov. 29, 2023
  • Dr. Juan Camilo Arjona Ferreira, chief medical officer, Organon
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip
    Q&A // First 90 Days

    Organon’s chief medical officer wants to change how the world sees women’s health

    Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

    By Nov. 22, 2023
  • COO, chief operating officer
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The biopharma COO’s playbook

    Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.

    By Alexandra Pecci • Nov. 21, 2023
  • Denise Bronner headshot
    Image attribution tooltip
    Permission granted by Johnson & Johnson Innovative Medicine
    Image attribution tooltip

    6 ways to improve clinical trial diversity — as shown by J&J

    Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.

    By Alexandra Pecci • Nov. 14, 2023
  • Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes
    Image attribution tooltip

    stock.adobe.com/master1305

    Image attribution tooltip
    Sponsored by ClinicalMind

    Optimizing KOL engagement and technology utilization in 2024

    What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

    Nov. 13, 2023
  • ceo pay
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 of the best paid biopharma CEOs

    As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

    By Alexandra Pecci • Nov. 10, 2023
  • Jean Jacques Bienaime headshot
    Image attribution tooltip
    Permission granted by BioMarin
    Image attribution tooltip
    Making Moves

    Does BioMarin’s CEO shuffle signal bigger changes ahead?

    With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

    By Nov. 9, 2023
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images
    Image attribution tooltip

    How pharma leaders talk about ethics in a highly criticized industry

    The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

    By Nov. 9, 2023
  • Sarah Boyce, CEO and president, Avidity Biosciences
    Image attribution tooltip
    Permission granted by Avidity
    Image attribution tooltip
    Biotech Spotlight

    A new delivery method muscling its way into the RNA space

    With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

    By Kelly Bilodeau • Nov. 8, 2023
  • Cancer research
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How Big Pharma keeps the oncology engines hot with a host of strategies

    From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

    By Nov. 2, 2023
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip

    Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

    Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.

    By Oct. 31, 2023
  • Adele Gulfo Red Jacket header
    Image attribution tooltip
    Permission granted by Sumitomo Pharma America
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Adele Gulfo, a commercialization guru

    With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

    By Karissa Waddick • Oct. 27, 2023
  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    By Oct. 27, 2023
  • Jeremy Levin, CEO and chairman, Ovid Therapeutics
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Dr. Jeremy Levin, a transformational leader

    A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.

    By Oct. 27, 2023
  • 2023 Red Jacket header
    Image attribution tooltip

    Photo illustration: Industry Dive

    Image attribution tooltip

    The 2023 Red Jacket honorees

    This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

    By Oct. 27, 2023
  • Dr. Mark Goldberg, CEO and chairman, Allucent
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Dr. Mark Goldberg, a clinical innovator

    Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

    By Alexandra Pecci • Oct. 27, 2023
  • Actor and epilepsy advocate Greg Grunberg
    Image attribution tooltip
    Permission granted by Greg Grunberg
    Image attribution tooltip
    Q&A

    Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

    The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

    By Oct. 19, 2023
  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2024

    A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

    By Ned Pagliarulo • Oct. 16, 2023
  • PV100 category rare disease warriors
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Rare disease warriors

    Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

    By Oct. 16, 2023
  • corporate brand
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    Branded: The trademarks pharma leaders look up to

    What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

    By PharmaVoice Staff • Oct. 13, 2023
  • Image attribution tooltip

    Permission granted by Mike Rea.

    Image attribution tooltip
    Q&A

    5 minutes with — IDEA Pharma’s Mike Rea

    The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

    By Oct. 11, 2023
  • conference crowd
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Key upcoming events for pharma execs

    Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

    By Oct. 6, 2023
  • Emil Kakkis
    Image attribution tooltip

    Permission granted by Dr. Emil Kakkis.

    Image attribution tooltip

    FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

    The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

    By Oct. 5, 2023